Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease–associated inflammation and lymphomagenesis
Georgia Malamut, … , Nadine Cerf-Bensussan, Bertrand Meresse
Georgia Malamut, … , Nadine Cerf-Bensussan, Bertrand Meresse
Published May 3, 2010
Citation Information: J Clin Invest. 2010;120(6):2131-2143. https://doi.org/10.1172/JCI41344.
View: Text | PDF
Research Article Gastroenterology

IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease–associated inflammation and lymphomagenesis

  • Text
  • PDF
Abstract

Enteropathy-associated T cell lymphoma is a severe complication of celiac disease (CD). One mechanism suggested to underlie its development is chronic exposure of intraepithelial lymphocytes (IELs) to potent antiapoptotic signals initiated by IL-15, a cytokine overexpressed in the enterocytes of individuals with CD. However, the signaling pathway by which IL-15 transmits these antiapoptotic signals has not been firmly established. Here we show that the survival signals delivered by IL-15 to freshly isolated human IELs and to human IEL cell lines derived from CD patients with type II refractory CD (RCDII) — a clinicopathological entity considered an intermediary step between CD and enteropathy-associated T cell lymphoma — depend on the antiapoptotic factors Bcl-2 and/or Bcl-xL. The signals also required IL-15Rβ, Jak3, and STAT5, but were independent of PI3K, ERK, and STAT3. Consistent with these data, IELs from patients with active CD and RCDII contained increased amounts of Bcl-xL, phospho-Jak3, and phospho-STAT5. Furthermore, incubation of patient duodenal biopsies with a fully humanized human IL-15–specific Ab effectively blocked Jak3 and STAT5 phosphorylation. In addition, treatment with this Ab induced IEL apoptosis and wiped out the massive IEL accumulation in mice overexpressing human IL-15 in their gut epithelium. Together, our results delineate the IL-15–driven survival pathway in human IELs and demonstrate that IL-15 and its downstream effectors are meaningful therapeutic targets in RCDII.

Authors

Georgia Malamut, Raja El Machhour, Nicolas Montcuquet, Séverine Martin-Lannerée, Isabelle Dusanter-Fourt, Virginie Verkarre, Jean-Jacques Mention, Gabriel Rahmi, Hiroshi Kiyono, Eric A. Butz, Nicole Brousse, Christophe Cellier, Nadine Cerf-Bensussan, Bertrand Meresse

×

Figure 9

Treatment of IL-15TgE mice with ABT-737 restores normal numbers of circulating CD8+ T, NK, and NKT cells.

Options: View larger image (or click on image) Download as PowerPoint
Treatment of IL-15TgE mice with ABT-737 restores normal numbers of circu...
(A) 3 IL-15TgE and 2 B6 mice were treated with daily i.p. injections of 75 mg/kg ABT-737 or vehicle, and absolute numbers of CD8+ T, NK, and NKT cells were determined in the blood on days 7 and 14. Treatment of IL-15TgE mice markedly decreased the number of circulating CD8+ T, NK, and NKT cells, which returned to that observed in B6 mice. No changes in the numbers or percentages of cells were observed in mice that received vehicle only (not shown). (B) For comparison, IL-15TgE mice were treated with 2 i.p. injections of AMG714 or control human IgG (n = 3 per group). AMG714, like ABT-737, preferentially decreased the number of CD8+ T, NK, and NKT cells in the blood of IL-15TgE mice, whereas control human IgG had no effect (not shown). (C) Treatment of IL-15TgE mice with ABT-737 induced a marked decrease of CD3+CD8+ T cells in spleen and mesenteric lymph nodes (MLNs), but had little or no effect on LPLs and IELs, compared with mice treated with vehicle. (D) IELs isolated from IL-15TgE mice were cultured in vitro for 48 hours in medium alone and supplemented with 20 ng/ml IL-15 in the presence of different concentrations of ABT-737. Results are representative of 2 independent experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts